Selpercatinib (Retevmo) 80mg — RET-Driven Cancer | China-Sourced | GLT

Generic Info

Selpercatinib, marketed under the brand name Retevmo, is an oral, highly selective RET kinase inhibitor. It was discovered by Eli Lilly and Company and, in March 2022, licensed to Innovent Biologics (Suzhou) Co., Ltd. for exclusive commercialization in Mainland China. The China National Medical Products Administration (NMPA) approved selpercatinib in October 2022 for RET-driven lung and thyroid cancers. This China-sourced version offers the same active ingredient with local commercial availability.

What Is Selpercatinib Used For?

Selpercatinib is used to treat cancers driven by RET gene alterations: RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC), and RET fusion-positive thyroid cancer. It is prescribed only after a molecular test confirms the presence of a RET fusion or mutation.

How Does Selpercatinib Work?

RET is a receptor tyrosine kinase that, when altered by a gene fusion or mutation, drives uncontrolled cancer cell growth. Selpercatinib is a highly selective RET kinase inhibitor that binds and blocks RET, shutting down downstream signaling that fuels tumor growth. It crosses the blood-brain barrier and has demonstrated high intracranial response rates against brain metastases.

Indications

• RET fusion-positive locally advanced or metastatic NSCLC
• RET-mutant advanced or metastatic medullary thyroid cancer (MTC)
• RET fusion-positive advanced or metastatic thyroid cancer (radioactive iodine-refractory, when applicable)

Dosage

The recommended dose in adults and adolescents 12 years and older is based on body weight: 120 mg orally twice daily for patients under 50 kg, and 160 mg orally twice daily for patients 50 kg or greater, until disease progression or unacceptable toxicity. Dose reductions are required for severe hepatic impairment.

Side Effects

The most common side effects include dry mouth, diarrhea, hypertension, fatigue, edema, constipation, rash, and elevated liver enzymes (ALT/AST). Serious side effects include hepatotoxicity, interstitial lung disease (ILD)/pneumonitis, hypertension, QT interval prolongation, hemorrhagic events, and hypersensitivity reactions. Liver function and blood pressure should be monitored regularly during treatment.

Storage

Store selpercatinib at room temperature (20°C to 25°C / 68°F to 77°F). Keep in the original container, tightly closed, and out of reach of children. Do not use after the expiration date printed on the package.

Why Choose the China Version of Retevmo?

This China-sourced Retevmo is commercialized in Mainland China by Innovent Biologics under its exclusive license from Eli Lilly, with NMPA approval and established local supply channels. GIVE LIFE TIME LIMITED (GLT) sources this version for international buyers seeking a reliable China-based supply, with full documentation and responsive service for both institutions and individual patients.

How to Order

Contact our team via WhatsApp or email to confirm current availability, pricing, and shipping options for your region. Provide the required strength and quantity, and we will guide you through the ordering and delivery process.

FAQ

Q: Is Retevmo a chemotherapy?
No. Selpercatinib is a targeted therapy (a RET kinase inhibitor), not a conventional chemotherapy.

Q: Who can take Retevmo?
It is for patients whose cancer has a confirmed RET gene fusion or RET mutation, as detected by a molecular test.

Q: How is Retevmo taken?
It is taken orally, twice daily, with the dose based on body weight (120 mg or 160 mg twice daily for adults).